برنامج تطوير مهنة الصيدلة - PPDPROGRAM

➡️Eysuvis (loteprednol etabonate) Ophthalmic Suspension Date of Approval: October 26, 2020 Company: Kala Pharmaceuticals, Inc. Treatment for: Dry Eye Disease Eysuvis (loteprednol etabonate) is an ophthalmic corticosteroid formulation for the temporary relief of signs and symptoms of dry eye disease. https://t.me/ppdprogram

➡️Sogroya (somapacitan-beco) Injection Date of Approval: August 28, 2020 Company: Novo Nordisk Treatment for: Adult Human Growth Hormone Deficiency Sogroya (somapacitan-beco) is a human growth hormone analog indicated for the replacement of endogenous growth hormone in adults with growth hormone deficiency. https://t.me/ppdprogram

➡️Winlevi (clascoterone) Cream Date of Approval: August 26, 2020 Company: Cassiopea SpA Treatment for: Acne Winlevi (clascoterone) cream is a first-in-class topical androgen receptor inhibitor indicated for the topical treatment of acne vulgaris in patients 12 years of age and older. https://t.me/ppdprogram

➡️Evrysdi (risdiplam) for Oral Solution Date of Approval: August 7, 2020 Company: Genentech Treatment for: Spinal Muscular Atrophy Evrysdi (risdiplam) is a survival of motor neuron 2 (SMN2) splicing modifier indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients. https://t.me/ppdprogram

➡️Mycapssa (octreotide) Delayed-Release Capsules Date of Approval: June 26, 2020 Company: Chiasma, Inc. Treatment for: Acromegaly Mycapssa (octreotide) is an oral formulation of the approved somatostatin analog octreotide for the treatment of acromegaly. https://t.me/ppdprogram

➡️Fintepla (fenfluramine) Oral Solution Date of Approval: June 25, 2020 Company: Zogenix, Inc. Treatment for: Dravet Syndrome, Lennox-Gastaut Syndrome Fintepla (fenfluramine) is an amphetamine derivative indicated for the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome in patients 2 years of age and older. https://t.me/ppdprogram

➡️Gimoti (metoclopramide) Nasal Spray Date of Approval: June 19, 2020 Company: Evoke Pharma, Inc. Treatment for: Gastroparesis Gimoti (metoclopramide) is an intranasal formulation of the approved drug metoclopramide for the relief of symptoms of acute and recurrent diabetic gastroparesis in adults. https://t.me/ppdprogram

➡️Lyumjev (insulin lispro-aabc) Injection Date of Approval: June 15, 2020 Company: Eli Lilly and Company Treatment for: Diabetes, Type 1, Diabetes, Type 2 Lyumjev (insulin lispro-aabc) is a rapid-acting human insulin analog indicated to improve glycemic control in adults with diabetes mellitus. https://t.me/ppdprogram

➡️Semglee (insulin glargine-yfgn) Injection Date of Approval: June 11, 2020 Company: Mylan Pharmaceuticals Inc. Treatment for: Diabetes, Type 1, Diabetes, Type 2 Semglee (insulin glargine-yfgn) is a long-acting human insulin analog biosimilar to Lantus (insulin glargine) indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus, and adults with type 2 diabetes mellitus. https://t.me/ppdprogram

➡️Zilxi (minocycline) Topical Foam - formerly FMX103 Date of Approval: May 28, 2020 Company: Foamix Pharmaceuticals Ltd. Treatment for: Rosacea Zilxi (minocycline) is a topical tetracycline formulation indicated for the treatment of inflammatory lesions of rosacea in adults. https://t.me/ppdprogram

➡️(artesunate) for Injection Date of Approval: May 26, 2020 Company: Amivas (US), LLC Treatment for: Malaria Artesunate for Injection is an antimalarial indicated for the initial treatment of severe malaria in adult and pediatric patients. https://t.me/ppdprogram

➡️Kynmobi (apomorphine hydrochloride) Sublingual Film Date of Approval: May 21, 2020 Company: Sunovion Pharmaceuticals Inc. Treatment for: Parkinson's Disease Kynmobi (apomorphine sublingual film) is a novel formulation of the approved dopamine agonist apomorphine for the on-demand management of OFF episodes associated with Parkinson’s disease (PD). https://t.me/ppdprogram

➡️Qinlock (ripretinib) Tablets Date of Approval: May 15, 2020 Company: Deciphera Pharmaceuticals, Inc. Treatment for: Gastrointestinal Stromal Tumor Qinlock (ripretinib) is a broad-spectrum KIT and PDGFRα inhibitor for the treatment of patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib. https://t.me/ppdprogram

➡️Retevmo (selpercatinib) Capsules Date of Approval: May 8, 2020 Company: Eli Lilly and Company Treatment for: Non-Small Cell Lung Cancer, Thyroid Cancer Retevmo (selpercatinib) is a kinase inhibitor for the treatment of patients with advanced RET fusion-positive non-small cell lung cancer (NSCLC), RET-mutant medullary thyroid cancer (MTC) and RET fusion-positive thyroid cancer. https://t.me/ppdprogram

➡️Darzalex Faspro (daratumumab and hyaluronidase-fihj) Injection Date of Approval: May 1, 2020 Company: The Janssen Pharmaceutical Companies of Johnson & Johnson Treatment for: Multiple Myeloma; Light Chain (AL) Amyloidosis Darzalex Faspro (daratumumab and hyaluronidase-fihj) is a combination of daratumumab (a CD38-directed cytolytic antibody) and hyaluronidase (an endoglycosidase) indicated for the treatment of multiple myeloma and light chain (AL) amyloidosis. https://t.me/ppdprogram

➡️Bafiertam (monomethyl fumarate) Delayed-Release Capsules Date of Approval: April 28, 2020 Company: Banner Life Sciences LLC Treatment for: Multiple Sclerosis Bafiertam (monomethyl fumarate) is a novel fumarate indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. https://t.me/ppdprogram

➡️Ongentys (opicapone) Capsules Date of Approval: April 24, 2020 Company: Neurocrine Biosciences, Inc. Treatment for: Parkinson's Disease Ongentys (opicapone) is a catechol-O-methyltransferase (COMT) inhibitor indicated as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease (PD) experiencing “off” episodes. https://t.me/ppdprogram

➡️Tukysa (tucatinib) Tablets Date of Approval: April 17, 2020 Company: Seattle Genetics, Inc. Treatment for: Breast Cancer Tukysa (tucatinib) is a kinase inhibitor indicated in combination with trastuzumab and capecitabine for the treatment of patients with advanced unresectable or metastatic HER2-positive breast cancer. https://t.me/ppdprogram

➡️Jelmyto (mitomycin) for Pyelocalyceal Solution Date of Approval: April 15, 2020 Company: UroGen Pharma Ltd. Treatment for: Urothelial Carcinoma Jelmyto (mitomycin) is a novel formulation of the approved alkylating drug mitomycin for the treatment of patients with low-grade upper tract urothelial cancer (LG-UTUC). https://t.me/ppdprogram

➡️Koselugo (selumetinib) Capsules Date of Approval: April 10, 2020 Company: AstraZeneca and Merck Treatment for: Neurofibromatosis Type 1 Koselugo (selumetinib) is an inhibitor of mitogen-activated protein kinase kinases 1 and 2 (MEK1/2) indicated for the treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). https://t.me/ppdprogram